14% growth masks lumpy earnings; Europe investments ahead of demand

Delivered ₹662.4 Cr, 14.1% YoY growth

Delivered ₹89 Cr EBITDA (13.4% margin), prior Q1 12.6%

Management qualified Flavour growth as lumpy with timing-driven orders; sustainable base is 15-17% lower

Delivered result corroborates; management chose pricing discipline over volume to maintain margins

Management acknowledged some client resistance but does not disclose volume loss magnitude

On track: Q1 delivers 14% growth, 13.4% EBITDA margin. However, excludes ₹30 Cr insurance gain; normalized PAT only ₹15.4 Cr (~2.3% margin vs 6.8% reported)

₹852 Cr vs ₹800 Cr prior guidance. Strategic inventory buildup (₹65 Cr added) + capex continued. Deleveraging path reaffirmed (₹25 Cr/qtr from Q3), so not a cut.

Flat YoY (vs group +14% growth). Management exited low-margin business proactively; nonetheless, signals domestic market headwind vs prior calls' implied strength.

₹112 Cr Q1 headline; ₹95-96 Cr normalized sustainable. Management candid on inventory pull-forward, but Q2+ guidance is not formally lowered.

"Softer quarter" vs prior calls' gradual recovery narrative. Now expects H2 turnaround; supply gap continues Q1-Q2.

Germany breakeven by YE26/early FY27; USA & UK a year later each. No acceleration or slip signaled vs prior calls.

Q1 was ₹112 Cr. Normal basis ~₹95 Cr. ~₹15 Cr is inventory buildup/order preponement. Q2+ normalizes.

9% is like-for-like growth; 5% is FX sales uplift. Rest is pricing/volume.

Q1 last year was strong. We consciously exited low-margin business, rationalized sales, disciplined on pricing. Servicing all clients now post-inventory buildup.

If double-digit growth sustained, margins will improve beyond Q1. But can't predict beyond 2-3 months. Cautious on macro.

Stable YoY, supported by product mix and proactive RM planning. Our 6-month fixed contracts + extra 45-day buffer hedge shocks.

Vanvate commissioning Q3 FY27. Debt remains ~June level (₹852 Cr), slightly up Sept. Deleveraging from Q3 onwards (₹25 Cr/qtr). ETR 31.5-32%, target <30%.

UK/USA market ~20-21% of global fragrance demand vs India 5%. $10B market size; targeting $100M addressable segment over 2-3 years. Skillsets adequate; R&D & patents enable $10B eventual reach over 10 years.

Premiumization is normal trend with higher disposable income. Muted in high-inflation years. Europe already developed wave-2 products now cross-selling to Asia.

About 10-11%.

6-month fixed contract visibility + inventory. RM costs fixed for next 6 months from July. Extra 45-day buffer allows recalibration time. No big margin shock expected.

Correct logic. If growth sustains, margins will improve. But can't predict full-year due to macro uncertainty. Guarded stance.

Q1: ₹25 Cr in Europe (now completed, operational since May). Q2: ₹25 Cr in Vanvate. Remaining ~₹50 Cr in 3 India plants, decision to defer some to Q1 next year.

Long-term ROCE 17-18% in Europe. Full capex cycle done (Germany CDC, Almere factory). 3-4 years to normalize trend line. $3M/yr additional R&D spend. $4-5B new market addressable.

Long-term target 20% ROCE. Near-term 3-5 years path to 15%. Then ramp-up post breakeven in new ventures.

No impact so far.

Currently ₹35 Cr/qtr. Post-Vanvate capitalization, expect ₹38-39 Cr/qtr run-rate.

Three new market ventures (Germany, USA, UK) must achieve EBITDA breakeven YoY by year 3. Germany this/next year, USA a year later, UK another year later. This is our milestone.

Major macro disruptions (pandemic-like). Business is repeat annuity; once launched, it sustains. Disruptions affect current + subsequent year pipeline. Stable macro = we can double revenue in 5 years.

~50 lakh shares. ₹30 Cr value of borrowing against shares.

Debt will remain elevated next quarter (similar to June ₹852 Cr), may rise slightly Sept. From Q3, reduce ~₹25 Cr/qtr thereafter.

Corrected pricing based on cost inflation from geopolitical effect. 95%+ clients accepted. Where reluctant, withheld supply until negotiations complete. Part of reason India Fragrance sales lower.

Supply chain disruptions hit Global Ingredients directly. Backward integration (away from China) in place. Disruptions created supply gap; recovery expected H2 FY27.

₹50-60 Cr pending. Will chase insurers for fulfillment within FY27.

Continuous stream of projects with Unilever + others. No large breakthrough additions yet. Global clients facing pricing pressure, new product launches muted (especially India).

Germany truly on way with regular traction. USA: expect ₹1.5-2 million (≈₹12-16 Cr annually) FY27. UK: just started this year; expect 12-15 months before material business.

Q2 may be even stronger than ₹95 Cr. Guesstimate ~₹15 Cr of Q1's ₹112 Cr is extra stock buildup. Normalized ₹95-97 Cr. Q2 better than ₹95-96, Q3 better than Q2, etc. Don't expect ₹112+ repeat in Q2.

Started with some global nutrition companies; nothing substantial yet. Flavour products are new introductions; 3-4 years to material value.

Across the board, business as usual. Global Ingredients lower than expected. Otherwise, no specific segment standout. Normal quarter with Flavours outperforming, Global Ingredients below budget.

Q1 delivered 14.1% YoY. Management reaffirmed double-digit for full year despite macro caution. Flavour base normalizing ₹95-96 Cr/qtr post Q1 lumpiness.

Q1 at 13.4% (vs guided 13.5% for H1). Management cautious on full-year prediction beyond 2-3 months. Macro & segment softness (Global Ingredients) create downside risk.

Q1: ₹25 Cr (Europe, now complete). Q2: ₹25 Cr (Vanvate). ~₹50 Cr remaining (3 India plants); some deferrable to Q1 FY28.

Geopolitical developments in West Asia driving energy, freight volatility. Product pipeline & launches defer in disruption periods. Repeat-annuity business vulnerable to sudden shocks.

₹15 Cr of ₹112 Cr Q1 Flavour revenue is inventory buildup from customers preponing orders due to supply uncertainty. Normalized ₹95-96 Cr. If customer demand weakens post inventory fill, Q2+ miss guidance.

Softer quarter on lower demand in select export markets. Backward integration (away from China) underway but disruptions created supply gap. Recovery expected H2, but timing uncertain.

Flat YoY growth (vs group +14%) despite conscious exit from low-margin business. Q1 prior year was strong base, but India fragrance growth lagging globally. Pricing passed to 95%+ clients; remaining 5% withheld supply (implied volume loss).

Net debt ₹852 Cr vs ₹800 Cr prior guidance. Strategic inventory (₹65 Cr) + capex acceleration pushed leverage higher. Deleveraging target ₹25 Cr/qtr from Q3; but macro disruption could delay cash generation.

Germany, USA, UK development centers in early ramp-up (invested heavily 2+ years). Germany targeting breakeven by YE26/early FY27. USA minimum ₹12-16 Cr FY27; UK nascent (12-15 months to material business). If adoption slower than expected, ventures will drag group ROCE for 3-4 years.